Follow on Google News News By Tag * Amgen * Amgen Biotech Leader Market Analysis * Largest Biotech Company * International Pharmaceutical Company * Amgen Drugs * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News |  Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023Visiongain is pround to announce the release of the brand new report "Amgen The Biotech Leader".In 2007, Amgen Inc - the world’s largest biotechnology company achieved total sales of $14.7m.
By: Visiongain Ltd. In 2007, Amgen Inc - the world’s largest biotechnology company - achieved total sales of $14.7m, despite a turbulent year marked by regulatory, pricing and reimbursement issues. Amgen has now firmly established itself as a Top-20 international pharmaceutical company. According to sales data for 2007, Amgen is also ranked as the 11th largest pharmaceutical company worldwide based on total sales value. This is a remarkable achievment for a biotechnology company founded in 1980. This independent and unique report will help you to understand why Amgen is so competitive and what roles it and similar companies will play in the global pharmaceutical market from the present onwards. Amgen is a vital company for competitive analysis and as an indicator of success factors required in the new competitive environment in healthcare. Our new report Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023 will help you to understand those developments and their significance for the biotechnology and pharmaceutical industries, as well as related sectors. Amgen’s proprietary products comprise human therapeutic drugs: • Epogen (epoetin alfa) • Aranesp (darbepoetin alfa) • Neupogen (filgrastim) • Neulasta (pegfilgrastim) • Kineret (anakinra) • Enbrel (etanercept) Visiongain believes that the combined revenues for Amgen's key drugs will reach $20bn by 2012. Amgen’s leadership in the biotech sector over the years has been driven largely by well-thought out strategic activities. Those corporate developments comprise key mergers and acquisitions (M&As) and strategic alliances. Amgen, although presently going through restructuring in some of its departments, clearly has a robust corporate strategy that should serve it well for years to come, driving strong growth and further innovation. Moreover, Amgen has a noteworthy commercial R&D pipeline that should generate significant dividends in the long-term, visiongain believes. Our new Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023 report examines that company critically, with in-depth analysis. Importantly, visiongain discusses Amgen in the context of the wider pharmaceutical market. This totally independent market-based research involved a detailed study of commercial documents, databases, company reports and relevant news. Importantly, visiongain applied techniques such as financial forecasting, study of market shares, SWOT analysis and qualitative projections. The result is a comprehensive market-based report with detailed analyses and informed opinion. Why you should buy this report: In particular, Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023 concentrates on the following essential aspects of Amgen and the market in which it competes: • Detailed analysis of Amgen’s present challenges, achievements and future prospects • Corporate Sales forecast for Amgen • Sales forecasts for leading drugs • Discussions of issues affecting the relevant market segments • Competitor analysis • Drivers and opportunities for Amgen • Restraints and threats facing the company • Discussions of corporate strategy in the context of the market • Strategic alliances and licensing • Pipeline developments and their implications for the future • International operations • Litigation proceedings Amgen, a leader in biotechnology, will generate high revenues and significant profitability in the years ahead, visiongain concludes. Sales of biotech drugs are increasing worldwide, with greater reliance on those agents as time goes by. Certainly, the future prospects for leading biotech companies are vast, especially with the dawn of more-personalised molecular medicine with greater efficacy and safety profiles. Also, there are increasing numbers of niche markets for biotech drugs, especially for serious, difficult-to- Companies Listed Abbott Abgenix Abraxis BioScience Inc Actelion Ltd. Alantos Alcon Alpharma Amgen Oncology Assistance Program Amylin Pharma Inc. Ariad Pharmaceuticals AstraZeneca Avida Bayer BioGeneriX Biopartners Biovitrum Boehringer Ingelheim Bristol-Myers Squibb (BMS) Burrill Personalised Medicine Index Cangene Cardiovascular and Renal Drugs Advisory Committee (CRDAC) Celgene Corp Centor Cephalon Inc. Chugai Connetics CSL Ltd. Cytokinetics Daiichi Sankyo Danish Head and Neck Cancer Group (DAHANCA) Dava Dragon Pharmaceuticals Drug Safety and Risk Management Advisory Committee (DSaRMAC) Duramed DxS Eisai Elan Corp. Eli Lilly Amgen Encourage Foundation European Agency for the Evaluation of Medicinal Products (EMEA) Fresenius Medical Care Galapagos services division of BioFocus GeneMedix Genentech Genzyme German Gynaecology Oncology Group Gilead Sciences Inc. GlaxoSmithKline Grope d'Etudes des Lymphomes de l' Adulte (GELA) Gyaenacology Oncology Group (GOG) Hexal Biotech Hospira Enterprise Human Genome Science Ilypsa ImClone Systems Inc Immunex InterKrin Therapeutics InterMune J&J pharmaceutical research and development (J&JPRD) Janssen-Cilag Johnson& Johnson (J&J) Kinetix Kirin Brewery Kyowa Hakko Kogyo Lab21 LG Chemicals MedImmune Merck & Co Merck KGaA Merck Serono (EMD Serono) MGI Pharma Inc. Millennium Pharma Inc Novartis Novo Nordisk Oncologic Drugs Advisory Committee (ODAC) Ortho Biotech Ortho Pharmaceuticals OSI Pharmas Inc Oxford Genome Sciences PDL BioPharma Inc Pfizer Inc Pliva Rhein Biotech Regeneron Roche Roemmers Safety Net foundation Sandoz Sanofi-Aventis Schering Plough Serono SA Servier Shire Stada Synergen Syntex Takeda TAP Pharmaceutical Techne Teva Tularik UCB SA US Centres for Medicare and Medicaid Services (CMS) US Food And Drug Administration (FDA) West German Study Group (WSG ) Wockhardt Wyeth Yeda Visiongain ltd. 4th Floor, BSG House, 226 236 City Road, London EC1V 2QY United Kingdom Telephone: +44 (0) 20 7336 6100 Fax: +44 (0) 20 7549 9930 info@visiongainglobal.com Or Visit at: http://www.visiongain.com/ Or http://www.visiongain.com # # # Visiongain is an independent business information provider for the Telecoms, Pharmaceutical and Defence industries. We organise conferences, publish reports and newsletters, and provide consultancy services. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||
